Chicago, ILNCT05720117Now EnrollingIRB Ready

Solid Tumor Clinical Trial in Chicago, IL

Access cutting-edge solid tumor treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Pyxis Oncology, Inc

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access solid tumor specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related solid tumor treatment provided free

Apply for This Chicago Location

Check if you qualify for this solid tumor clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Solid Tumor Study in Chicago

The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

Sponsor: Pyxis Oncology, Inc

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed solid tumors including locally advanced/metastatic HR+ and HER2- breast cancer (post CDK4/6 inhibitor +/- ET, ≤ 2 lines systemic therapy), TNBC (1-3 prior lines including post ADC topo-1 payload), HNSCC (1-2 prior lines including post PD-L1/PD1 and platinum based therapy), and other solid tumor types (≤ 2 lines systemic therapy).
Male or non-pregnant, non-lactating female participants age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1.
Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Life expectancy of \>3 months, in the opinion of the Investigator.
Corrected QTcF \<470 msec.
Adequate hematologic function.
Adequate hepatic function.
Adequate renal function.
Adequate coagulation profile.
Clinical sites must conduct fresh tumor biopsy or provide participant's archived tumor tissue sample.

Exclusion Criteria

History of another malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin; in situ cervical carcinoma; adequately treated, noninvasive bladder cancer.
Known symptomatic brain metastases.
Significant cardiovascular disease within 6 months prior to start of study drug.
Evidence of an active systemic bacterial, fungal, or viral infection requiring treatment at the start of study drug.
Known active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
Failure to recover to baseline severity or Grade ≤1 NCI-CTCAE v5.0 from acute non-hematologic toxicity.
Participants with NCI-CTCAE v5.0 Grade \>1 neuropathy of any etiology.
Prior solid organ or bone marrow progenitor cell transplantation.
Prior high-dose chemotherapy requiring stem cell rescue.
Received systemic anticancer therapy within 28 days or within 5 half-lives (whichever is shorter) prior to the start of study drug.
Palliative radiation therapy within 14 days prior to the start of study drug.
Previously received extra domain B splice variant of fibronectin (EDB+FN) targeting treatments at any time prior to the start of PYX-201 treatment.
History of uncontrolled diabetes mellitus.
History of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Participants with corneal epithelial disease, with the exception of mild punctate keratopathy
Participants with the best-corrected visual acuity in the worst-seeing eye worse than 20/100 (Snellen equivalent).
Participants with a history of (noninfectious) pneumonitis/ interstitial lung disease that required steroids, has current pneumonitis/ interstitial lung disease, or evidence of active pneumonitis on screening chest CT scan or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT05720117) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Solid Tumor Treatment Options in Chicago, IL

If you're searching for solid tumor treatment options in Chicago, IL, this clinical trial (NCT05720117) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all solid tumor clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Chicago, IL

See all advanced solid tumors clinical trials recruiting in Chicago — not just this study.

Browse Advanced Solid Tumors Trials in Chicago →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL